Novartis, CH0012005267

Novartis stock: UBS keeps Hold rating and CHF 116.00 target for Novartis stock

Published on 10/21/2026 at 16:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis reports results on October 27, 2026. Novartis stock costs EUR 136.48 on October 21, 2026, minus 0.01 percent versus the Xetra close.

Analyst target and reporting date

UBS maintained a Hold rating and a CHF 116.00 target on October 20, 2026.
Novartis reported CHF 14.16 billion in second-quarter revenue versus CHF 14.84 billion a year earlier.
Novartis stock costs EUR 136.48 at Lang & Schwarz on October 21, 2026 at 4:06 p.m. CEST, 0.01 percent below the Xetra close of October 20, 2026.
Novartis is scheduled to hold a Remibrutinib investor call on October 23, 2026.

Forscherin in weißem Kittel pipettiert in Reagenzglas im sterilen Pharmalabor — Novartis AG CH0012005267 – Forscherin pipettiert präzise in steriler Pharmalaborumgebung mit Reagenzgläsern, Illustration mit AI erstellt.

UBS maintained a Hold rating on Novartis AG and set a CHF 116.00 price target in a report dated October 20, 2026, according to Markets Insider. The target is 8.18 percent below the CHF 126.34 SIX price listed for October 20, 2026. At Lang & Schwarz, Novartis stock was trading at EUR 136.48 on October 21, 2026 at 4:06 p.m. CEST, 0.01 percent below the Xetra close of October 20, 2026 at EUR 136.50.

Second-quarter figures set the base

Novartis reported CHF 14.16 billion in revenue and CHF 3.21 billion in net profit for the quarter ended June 30, 2026, according to Markets Insider. Revenue was below the CHF 14.84 billion reported for the same quarter a year earlier, while net profit fell from CHF 4.04 billion. The comparison gives the UBS rating a more cautious operating backdrop ahead of the next report.

What does the CHF 116.00 target imply?

The target sits below the dated SIX price, but it does not alter the immediate euro quotation. The Lang & Schwarz move was limited to minus EUR 0.02 against the Xetra close, equivalent to minus 0.01 percent. Novartis remains a healthcare company focused on prescription medicines across oncology, immunology, neuroscience and cardiovascular care.

Two dates shape the next update

Novartis lists a Remibrutinib in multiple sclerosis investor call for October 23, 2026. The company schedules its third-quarter results for October 27, 2026, with the investor calendar placing the event in Basel, Switzerland, according to Novartis. Those dates provide the next company-specific checkpoints for the analyst view and the revenue trend.

Novartis market position

Novartis AG is listed on SIX under the ticker NOVN and operates in the Healthcare sector. Its primary business is developing, manufacturing and marketing prescription medicines, while the October 23 investor call is expected to center on remibrutinib in multiple sclerosis.

At Lang & Schwarz, Novartis stock was trading at EUR 136.48 on October 21, 2026 at 4:06 p.m. CEST, 0.01 percent below the Xetra close of October 20, 2026 at EUR 136.50. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.